PortViewPortView
Exicure logo

Exicure (XCUR) Stock Analysis

NASDAQHealthcareBiotechnology

$1.31+0.78%
1-year price historyRange $1.15 – $7.29
52-week range$1.31
$1.05$9.48

What Exicure does

Exicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company has a co-development agreement with Adbiotech Co., Ltd. to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas. Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California.

Key metrics

Market cap
$8.35M
P/E (TTM)
-0.99
EPS (TTM)
$-1.32
Beta
3.66
Dividend yield
0.00%
Revenue / share
$0.00
50-day avg
$1.66
200-day avg
$3.59
52-week high
$9.48
52-week low
$1.05
CEO
Jungsoo Kim

ETFs linked to XCUR

Broad-market and Healthcare sector ETFs an investor holding Exicure is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how XCUR fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze XCUR in PortView →

Similar companies

Frequently asked questions

What is the ticker symbol for Exicure?
Exicure trades under the ticker XCUR on NASDAQ.
Which exchange is XCUR listed on?
XCUR is listed on NASDAQ.
What sector does Exicure operate in?
Exicure is classified in the Healthcare sector (Biotechnology industry).
How can PortView help analyze XCUR in a portfolio?
PortView shows XCUR's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.